Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    13

Stocks News & Analysis

stocks

The trillion-dollar club: Are these mega-sized stocks still buys?

The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
stocks

New pricing model for embattled ASX tech leader

Investor day shows off potentially disruptive pricing model.
stocks

Chart of the Week: We see opportunity in Mineral Resources despite debt concerns

Shares trade at a discount despite attractive longer-term outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,926.1019.300.22%
CAC 408,154.9032.870.40%
DAX 4024,029.72147.690.62%
Dow JONES (US)47,850.9431.96-0.07%
FTSE 1009,727.4816.610.17%
HKSE26,085.08149.180.58%
NASDAQ23,505.1451.040.22%
Nikkei 22550,491.87536.55-1.05%
NZX 50 Index13,483.9931.63-0.23%
S&P 5006,857.127.400.11%
S&P/ASX 2008,634.6020.500.24%
SSE Composite Index3,902.8127.010.70%

Market Movers